Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 27, 2017
Pharmacy Choice - News - Pharmaceutical Development - May 27, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/27/17 - Active Biotech: Interim report January - March 2017
The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis are expected in the first half of 2017 The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary...
4/27/17 - Biotech Firm Preparing for Next Stage of Development
PROPANC BIOPHARMA, INC.' S LATEST MILESTONES The name change announced earlier this month is official, as they are now operating as Propanc Biopharma Inc.. **Approved patent allowance in the US for lead product PRP which aims to prevent tumor recurrence and metastasis in solid tumors.** Successful completion of low dose group for GLP-compliant 28-
4/27/17 - Combine Solicitation - 68 RADIOPHARMACEUTICALS REQUEST FOR QUOTES
Office Address: Department of Veterans Affairs; Samuel S. Stratton VA Medical Center; 113 Holland Avenue; Albany NY 12208-3410. Description: Department of Veterans Affairs. Department of Veterans Affairs Medical Center.
4/27/17 - Dr. Reddy's Laboratories Announces the Launch of Ezetimibe and Simvastatin Tablets in the U.S. Market
HYDERABAD, India& PRINCETON, N.J. Dr. Reddy s Laboratories Ltd. announced today that it has launched Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg, a therapeutic equivalent generic version of Vytorin Tablets, in the United States market, approved by the U.S. Food and Drug Administration. The Vyto
4/27/17 - DrugDev to showcase transformative technology to improve clinical trials at premier upcoming pharma and biotech industry conferences in Europe
DrugDev executives and subject matter experts will share best practices for transforming clinical trials through collaboration, standardization, and a beautiful technology experience at premier upcoming European pharma and biotech industry events over the next two months. Avoca Quality Consortium 2017 Europe Summit Ibraheem "Ibs" Mahmood, DrugDev..
4/27/17 - Human Gene Therapy publishes review of randomized clinical trials of gene transfer for heart failure with reduced ejection fraction
By a News Reporter-Staff News Editor at Gene Therapy Weekly Newswire/ Renova? Therapeutics, a biotechnology company developing gene and peptide therapies for cardiovascular and metabolic diseases, announced its co-founder's online HYPERLINK " http://online.liebertpub.com/doi/10. 1089/ hum.2016.166"\ npublication of an article in Human Gene Th
4/27/17 - Murray Blasts Administration Action to Deny Consumers, Families Access to Clear Nutritional Information
Today, Senator Patty Murray,, ranking member of the Senate Health, Education, Labor, and Pensions Committee, issued the following statement on the Food and Drug Administration's issuance of an interim rule that will delay its final rule on menu labeling requirements, scheduled to take effect on May 5. "The tactic to delay this rule is disappoint
4/27/17 - Nicox first quarter 2017 business update and cash position
Nicox first quarter 2017 business update and cash position.
4/27/17 - Pharmaceutical Lifecycle Therapeutic and Drug Pipeline Review H1
Pharmaceutical Lifecycle Therapeutic Pipeline Market Review, H1 2017. PUNE, INDIA, April 27, 2017/ EINPresswire.com/ Summary " Pharmaceutical Lifecycle Management Strategies in 2017" provides a comprehensive assessment of product lifecycle management strategies that are being implemented by pharmaceutical companies around the world.
4/27/17 - Researchers Submit Patent Application, "Liner Discharge Structure for Attachment to Container Liner", for Approval (USPTO 20170096296)
By a News Reporter-Staff News Editor at Politics& Government Week From Washington, D.C., VerticalNews journalists report that a patent application by the inventor Lawrence, Jon, filed on October 6, 2015, was made available online on April 13, 2017. As a result of these concerns, governmental agencies such as the Food and Drug Administration have
4/27/17 - TherapeuticsMD Provides TX-004HR Regulatory Update
By a News Reporter-Staff News Editor at Women's Health Weekly TherapeuticsMD, Inc., an innovative women's healthcare company, announced that, on April 7, 2017, the Company received a letter from the U.S. Food and Drug Administration stating that, as part of the FDA's ongoing review of the Company's new drug application for TX-004HR, the Company's
4/27/17 - ZYDUS CADILA GETS USFDA NOD FOR ANTI-HYPERTENSIVE TABLETS
Pharmaceutical company Zydus Cadila has received final approval from the US Food and Drug Administration to market Olmesartan Medoxomil tablets in the US market. The approval is for 5 milligram, 20 milligram and 40 milligram strengths of the anti-hypertensive Olmesartan. estimated sales for Olmesartan is $982 million for twelve months to Feb 2017.
4/26/17 - Acceleron to Host Webcast to Review First Quarter 2017 Financial and Operational Results on May 8, 2017
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the Company will host a live conference call and webcast on Monday, May 8, 2017 at 8:00 a.m. EDT to discuss luspatercept Phase 2 data presen
4/26/17 - Addivant product receives FDA approval [New Times, The (Rwanda)]
Addivants nonylphenol-free stabiliser Weston 705 has received formal approval from the US Food and Drug Administration for use in infant formula and human milk plastics packaging. John Steitz, Addivants chief executive, said: FDA has tightened even further its scrutiny on infant formulation using the most stringent screening procedures for this...
4/26/17 - Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
Even with proper compliance, patients often have disease progression and require surgery,' said Keith Barton, M.D., glaucoma specialist at Moorfields Eye Hospital in London.' The CyPass Micro-Stent is a much-needed new option that is less invasive than traditional glaucoma surgery. 'The CyPass Micro-Stent is designed to address the greatest unmet n
4/26/17 - Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
Novartis International AG/ Alcon announces EU launch of CyPass Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure in patients with primary open-angle glaucoma. *Now available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure* CE indication has been
4/26/17 - Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today final 24- month results from its Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hATTR amyloidosis. These clinical data are being presented at the American Academy of Neurology 2017.
4/26/17 - Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegenerative Disease [Sudan Tribune]
Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced today that two additional pharmaceutical companies, Pfizer Inc. and AbbVie Inc., have invested in Aquinnah`s work to treat ALS, Alzheimer`s disease and other neurodegenerative diseases. This $10 million adds to a
4/26/17 - Aquinnah Pharmaceuticals Receives $10M Investment from Pfizer and Abbvie [Sport360]
Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced today that two additional pharmaceutical companies, Pfizer Inc. and AbbVie Inc., have invested in Aquinnahs work to treat ALS, Alzheimers disease and other neurodegenerative diseases. This $10 million adds to an.
4/26/17 - Aquinox to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference [Gulf Daily News (Bahrain)]
-Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President& CEO, will present a corporate overview at the upcoming 2017 Annual Bloom Burton& Co. Healthcare Investor Conference in...
4/26/17 - ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 200 th patient has been randomized into the GENETIC-AF clinical trial evaluating Gencaro? as potentially the first genetically-targeted treatment for atrial...
4/26/17 - ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Other Events
ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Other Events Item 8.01. Other Events. On April 26, 2017, ARCA biopharma, Inc. (ARCA) provided a GENETIC-AF clinical trial update.The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference. Section 9 Financial Statements and Exhibits Item 9.01. Fin
4/26/17 - ARCA BIOPHARMA, INC. FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On April 26, 2017, ARCA biopharma, Inc. provided a GENETIC-AF clinical trial update. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference. Exhibit Number Description 99.1 Press Release titled "ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2 B/
4/26/17 - Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients.
Arno Therapeutics Parsippany, NJ, USBiotechnologywww.arnothera.com Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients. &am...
4/26/17 - Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that the results from its completed Phase 2 clinical trial of AST-VAC1 are now available online in Cancer, a leading peer-reviewed journal of the American Cancer Society. The study publication is available at...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415